GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (BOM:524404) » Definitions » Additional Paid-In Capital

Marksans Pharma (BOM:524404) Additional Paid-In Capital : ₹0 Mil(As of Mar. 2025)


View and export this data going back to 1994. Start your Free Trial

What is Marksans Pharma Additional Paid-In Capital?


Marksans Pharma's annual additional paid-in capital stayed the same from Mar. 2023 (₹5,186 Mil) to Mar. 2024 (₹5,186 Mil) but then declined from Mar. 2024 (₹5,186 Mil) to Mar. 2025 (₹0 Mil).


Marksans Pharma Additional Paid-In Capital Historical Data

The historical data trend for Marksans Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma Additional Paid-In Capital Chart

Marksans Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,836.32 1,816.87 5,186.45 5,186.45 -

Marksans Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,186.45 - - - -

Marksans Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Marksans Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.

Marksans Pharma Headlines

No Headlines